Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. and YENHE Company signed 9 sets of drug comprehensive stability test chamber DWH-HQ500P

Anhui Zhifeilong Kema Biopharmaceutical Co., Ltd. (hereinafter referred to as "Zhifeilong Kema") is a high-tech enterprise integrating R&D, production and sales of biological products. It is a subsidiary of Chongqing Zhifei Biological Products Co., Ltd. (stock code: 300122 ) wholly-owned subsidiary. The company is mainly engaged in the research and development and production of biological products (immunological preparations, vaccines, genetically recombined products), with a registered capital of 765 million yuan and a factory area of 500.5 mu. The Biopharmaceutical Industrial Park will integrate R&D, production, logistics, sales and incubation to realize a multi-variety and large-scale production pattern. By then, the company will become a first-class vaccine enterprise in China, effectively promoting the development of the biopharmaceutical industry and contributing to the realization of the goal of "Healthy China".

In recent years, the company has successively obtained "High-tech Enterprise Certificate", "National Key New Product Certificate", "Anhui Province Innovative Pilot Enterprise", "Anhui Province New Human Vaccine Engineering Technology Research Center", "Hefei Enterprise Technology Center" , "Hefei City Informatization and Industrialization Integration Demonstration Enterprise" and a series of honors and certifications, and undertakes five national major infectious disease prevention and control projects and three national major new drug creation projects.